An observational study in Alzheimer's Disease, sponsored by Eisai Korea Inc.. Completed at 13 sites in Korea, Republic of. Per ClinicalTrials.gov, last updated 2017-03-07.
Sponsored by Eisai Korea Inc. · Observational
The purpose of the study is for investigation and collection of Aricept safety information with a dose increase on Alzheimer's disease patients.
This is an observational study to systematically investigate domestic patients with Alzheimer's disease to figure out the safety under a situation of the use of Donepezil HCl 23mg. Additionally, if the dose of Donepezil HCl increase, there is need to examine the safety of Donepezil HCl 23mg in depth for patients with Alzheimer's disease by comparing aspects of occurring adverse events by the type of Donepezil HCl increase.
3,678 studies on the registry are indexed under Alzheimer Disease; 869 are open to participants now.
This study's enrollment of 2,231 is above the median of 200 across 751 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Eisai Korea Inc. is the lead sponsor of 30 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Alzheimer's disease
Exclusion Criteria
Subjects starting at 5 mg Aricept and increasing their dose to 10 mg Aricept
Drug: Aricept
Subject starting at 10 mg Aricept and increasing their dose to 23 mg Aricept
Drug: Aricept
5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
Safety and tolerability due to an increase of Aricept in patients with Alzheimer's disease.
The aspects of adverse events between those who have increased Aricept dosage from 5mg to 10mg and those who have increased Aricept dosage from 10mg to 23mg will be compared. The subjects will be observed at least more than 12 weeks after Aricept administration. The patients who have obtained safety information through a visit after Aricept administration at least once will be selected as the subjects who can be assessed under the status of use.
Time frame: Up to 12 Weeks
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eisai Korea Inc.